97337 ⎘
Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Method of introducing nucleic acid into plant cells
#2102Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides
#2103CD20 scFv-ELPs METHODS AND THERAPEUTICS
#2104INTERLEUKIN-10 FUSION PROTEINS AND USES THEREOF
#2105Multivalent and Monovalent Multispecific Complexes and Their Uses
#2106Enhancement of transport of therapeutic molecules across the blood brain barrier
#2107Modified tafazzin proteins and methods of making and using the same
#2108Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
#2109Soluble notch receptor proproteins and methods of use thereof
#2110ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY
#2111HIGH PRESSURE REFOLDING OF MONOCLONAL ANTIBODY AGGREGATES
#2112HUMAN FUSION PROTEINS COMPRISING SINGLE CHAIN TNFALPHA AND TARGETING DOMAINS
#2113Targeted therapeutics
#2114AN IL-15 AND IL-15R\alpha SUSHI DOMAIN BASED IMMUNOCYTOKINES
#2115Anti-B7-H6 antibody, fusion proteins, and methods of using the same
#2116FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME
#2117Compound and method for treating myotonic dystrophy
#2118Composition for use in mycobacteria diagnosis
#2119Anti-alpha-synuclein antibodies and methods of use
#2120Methods of treating tumors with engineered antibody-interferon mutant fusion molecules
#2121Nanoemulsions
#2122Vaccine and uses thereof
#2123Methods of treating disease with fusion molecules comprising IL-15 variants
#2124Personalized immunotherapy against several neuronal and brain tumors
#2125Highly immunogenic peptides derived from the human immunodeficiency virus V2 region
#2126Cytokine-based fusion proteins for treatment of immune disorders
#2127Immunogenic control of tumours and tumour cells
#2128Modified exotoxin A
#2129Marker-suicide gene useful in adoptive cell therapy
#2130Compound and method for treating myotonic dystrophy
#2131Recombinant AAV capsid protein
#2132Aberrant cell-restricted immunoglobulins provided with a toxic moiety
#2133Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis
#2134B-cell receptor complex binding proteins containing T-cell epitopes
#2135Peptides for inhibiting tumor growth
#2136Compositions, methods and kits for treatment of cancer and autoimmune diseases
#2137Anti-mesothelin chimeric antigen receptors
#2138Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
#2139Bispecific chimeric proteins comprising DARPins
#2140Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
#2141Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
#2142Cytotoxins comprising modified bouganin toxin for the treatment of cancer
#2143HUMANIZED ANTIBODIES
#2144Serine protease molecules and therapies
#2145Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
#2146Targeting of chondroitin sulfate glycans
#2147NPP1 fusion proteins
#2148Vault compositions for immunization
#2149Compositions and methods for delivering inhibitory oligonucleotides
#2150Phage derived antimicrobial activities
#2151Erythrocyte-binding therapeutics
#2152Targeted/immunomodulatory fusion proteins and methods for making same
#2153Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell
#2154Vector containing multiple nucleotide sequences for the expression of enzymes
#2155Recombinant bacteria recognizing protein and uses thereof
#2156CELL KILLING FUSION PEPTIDE EXHIBITING TUMOR CELL-SPECIFIC NECROSIS INDUCTION AND TUMOR REGRESSION
#2157Fusion protein comprising circularly permuted form of trail/Apo2L, coding gene and use thereof
#2158Solubility enhancing peptide and use thereof
#2159TARGETED IDURONATE-2-SULFATASE COMPOUNDS
#2160Immune modulation via C-type lectin
#2161Recombinant polypeptides for membrane fusion and uses thereof
#2162Serine protease molecules and therapies
#2163IL-2 derivative polypeptides
#2164Non-natural MIC proteins
#2165Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
#2166Anti-bacterial polypeptides and pathogen specific synthetic antibodies
#2167Adeno-associated virus virions with variant capsid and methods of use thereof
#2168Methods for controlling T cell proliferation
#2169Prodrug activation in cancer cells using molecular switches
#2170Bio-pin
#2171Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
#2172Methods and compositions for targeting adipose cells in mammals
#2173Antibody-mediated transduction of heat shock proteins into living cells
#2174Engineered microbe-targeting molecules and uses thereof
#2175Multi-specific binding molecules targeting aberrant cells
#2176Nogo receptor antagonists and methods of increasing neurite outgrowth
#2177Suppression of prostate cancer using a targeted clostridial neurotoxin
#2178Targeted delivery of proteins across the blood-brain barrier
#2179HUMAN FUSION PROTEINS COMPRISING INTERFERONS AND TARGETED MODIFIED UBIQUITIN PROTEINS
#2180Fusion molecules and IL-15 variants
#2181Immunocytokine combination therapy
#2182Compositions and methods to immunize against hepatitis C virus
#2183Sequential antibody therapy
#2184Vaccine against multitypes of avian influenza viruses and uses thereof
#2185Designer collagens and use thereof
#2186Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#2187Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#2188Serine protease molecules and therapies
#2189Dimeric binding proteins based on modified ubiquitins
#2190Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
#2191Use of a trans-signaling approach in chimeric antigen receptors
#2192Biotherapy for pain
#2193Recombinant pokeweed antiviral proteins, compositions and methods related thereto
#2194exotoxin A with less immunogenic T cell and/or B cell epitopes
#2195Immunogenic compositions in particulate form and methods for producing the same
#2196Targeted interferons demonstrating potent apoptotic and anti-tumor activities
#2197Small molecule-dependent inteins and uses thereof
#2198Enzyme prodrug cancer therapy selectively targeted to tumor vasculature and methods of production and use thereof
#2199CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
#2200Vaccines directed to langerhans cells
#2201Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors
#2202Targeting pseudotyped retroviral vectors
#2203Re-directed immunotherapy
#2204Encryption of adeno-associated viruses with enzymatically decoded peptide locks
#2205Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels
#2206MIR-21 promoter driven targeted cancer therapy
#2207Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
#2208Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
#2209Anticancer fusion protein comprising trail and a growth factor receptor inhibitor
#2210Use of chimeric antigen receptor-modified T-cells to treat cancer
#2211DNA vaccine against multitypes of avian influenza viruses and influenza virus-like particles comprising adjuvant-fused M2 protein
#2212Interleukin 15 as selectable marker for gene transfer in lymphocytes
#2213Selective anticancer chimeric peptides which bind neuropilin receptor
#2214Selective anticancer chimeric peptides which bind transferrin receptor
#2215NPP1 fusion proteins
#2216Anticancer fusion protein comprising TRAIL and interferon
#2217Processable single chain molecules and polypeptides made using same
#2218Fusion proteins
#2219Methods and compositions for treating HIV
#2220Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
#2221Factor IX polypeptides and methods of use thereof
#2222Homodimeric protein constructs
#2223Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof
#2224Interferon lambada-antibody complexes
#2225Method for uses of proinsulin transferrin fusion proteins as prodrugs
#2226Peptide derivatives, preparation and uses thereof
#2227Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
#2228TRAIL R2-specific multimeric scaffolds
#2229CONJUGATE MOLECULE
#2230Baculoviruses with enhanced virion production and a method for the production of baculoviruses
#2231High affinity NY-ESO T cell receptors
#2232Activatable Constructs
#2233Treatment of metastatic tumors
#2234COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
#2235Lytic peptides having anti-proliferative activity against prostate cancer cells
#2236COMPLEXES COMPRISING MHC CLASS I FUSION POLYPEPTIDES AND ANTIGEN-SPECIFIC ANTIBODIES AND METHODS OF USE
#2237DELIVERY OF TRANSTHYRETIN ACROSS THE BLOOD-BRAIN BARRIER AS A TREATMENT FOR ALZHEIMER'S DISEASE
#2238Chimeric polypeptides and their use in bacterial decolonization
#2239Glucagon/GLP-1 receptor co-agonists
#2240Methods and compositions for the treatment and prevention of cancer
#2241Antibody-light fusion products for cancer therapeutics
#2242Peptides for targeting apoptotic cells and uses thereof
#2243Reducing the immunogenicity of fusion proteins
#2244COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS
#2245Monomeric Bi-Specific Fusion Protein
#2246Targeted delivery to human diseases and disorders
#2247Immunoconjugates
#2248RADIOLABELED COMPOUND DIRECTABLE IN VIVO TO TARGET TISSUE AND USE THEREOF
#2249IMMUNOTHERAPY
#2250Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#2251High pressure refolding of monoclonal antibody aggregates
#2252Cardiac-specific protein targeting domain
#2253Phage derived antimicrobial activities
#2254Fusion molecules and IL-15 variants
#2255Targeted particles and methods of using the same
#2256Lysosomal targeting peptides and uses thereof
#2257Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides
#2258Carcinoma homing peptide (CHP), its analogs, and methods of using
#2259ANTIMICROBIAL AGENTS
#2260Bifunctional polypeptides
#2261METABOLICALLY ACTIVATED RECOMBINANT VIRAL VECTORS AND METHODS FOR THEIR PREPARATION AND USE
#2262Antigen compositions and methods of inhibiting bacterial infection and uses of the antigen compositions
#2263TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS
#2264Modified Clostridial toxins with enhanced targeting capabilities for endogenous Clostridial toxin receptor systems
#2265Erythrocyte-binding therapeutics
#2266Fusion proteins containing recombinant cytotoxic RNAses
#2267Compositions and methods for treatment of cancer
#2268Monoclonal antibodies to dendritic cells
#2269Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
#2270TUMOR TARGETING PEPTIDES, THERAPEUTIC AND DIAGNOSTIC COMPOSITIONS COMPRESSING THE PEPTIDES
#2271Vault compositions for immunization against Chlamydia genital infection
#2272Targeted therapeutic proteins
#2273Use of IL-15 preparations to treat lymphopenia
#2274Polypeptides that Bind TRAIL-R1 and TRAIL-R2
#2275Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
#2276Modified non-cytotoxic proteases
#2277Soluble PD-1 variants, fusion constructs, and uses thereof
#2278Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
#2279Compositions of PD-1 antagonists and methods of use
#2280Compositions of PD-1 antagonists and methods of use
#2281METHOD OF PRODUCING HUMAN IGG ANTIBODIES WITH ENHANCED EFFECTOR FUNCTIONS
#2282TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS
#2283HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS
#2284MIR-21 promoter driven targeted cancer therapy
#2285Fusion proteins
#2286Compound and method for treating myotonic dystrophy
#2287Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
#2288POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION
#2289Erythrocyte-binding therapeutics
#2290Methods of using molecular conjugates comprising monoclonal antibodies to dendritic cells
#2291Humanized GM-CSF antibodies
#2292TARGETED NANOPARTICLES FOR CANCER AND OTHER DISORDERS
#2293Polypeptides that Bind TRAIL-R1 and TRAIL-R2
#2294Polypeptides for Specific Targeting to Otx2 Target Cells
#2295Method for Uses of Protein Precursors as Prodrugs
#2296Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide
#2297Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof
#2298Methods and materials for generating T cells
#2299Non-natural MIC proteins
#2300REGULATION OF PROTEIN LEVEL
#2301Compositions and methods for treatment of angiogenesis-associated ocular disorders
#2302DEGRADABLE CLOSTRIDIAL TOXINS
#2303USE OF BACTERIA FOR THE SENSING AND KILLING OF CANCER CELLS
#2304Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#2305Recombinant pokeweed antiviral proteins, compositions and methods related thereto
#2306Multimeric protein toxins to target cells having multiple identifying characteristics
#2307Chimeric activators: quantitatively designed protein therapeutics and uses thereof
#2308COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY
#2309Method for treating prostatitis utilizing modified pore-forming protein proaerolysin
#2310COMPOSITIONS CONTAINING THROMBOMODULIN DOMAINS AND USES THEREOF
#2311High affinity NY-ESO T cell receptors
#2312Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
#2313TARGETED COSTIMULATORY POLYPEPTIDES AND METHODS OF USE TO TREAT CANCER
#2314LYSOSOMAL TARGETING PEPTIDES AND USES THEREOF
#2315PD-1 ANTAGONISTS AND METHODS OF USE THEREOF
#2316Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors
#2317MATERIALS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY AND TAXANE-INDUCED PERIPHERAL NEUROPATHY (TIPN)
#2318Peptides that target dorsal root ganglion neurons
#2319TB VACCINE
#2320Antigenic compositions and use of same in the targeted delivery of nucleic acids
#2321MULTIPLE TARGET T CELL RECEPTOR
#2322Non-natural MIC proteins
#2323Class of therapeutic protein based molecules
#2324Non-cytotoxic protein conjugates
#2325TREATING CANCER STEM CELLS USING TARGETED CARGO PROTEINS
#2326Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
#2327Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
#2328ADENOVIRUS TARGETING
#2329PD-1 ANTAGONISTS AND METHODS FOR TREATING INFECTIOUS DISEASE
#2330FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME
#2331Compositions and methods for delivering inhibitory oligonucleotides
#2332NOVEL ANTI-ALLERGIC AGENTS
#2333Prodrug activation in cancer cells using molecular switches
#2334Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
#2335METHODS OF LONG-TERM CULTURE OF EUKARYOTIC CELLS AND USES THEREOF
#2336Stereoisomer peptides, ligand-targeted multi- stereoisomer peptide polymer conjugates, and uses thereof
#2337Metabolically activated recombinant viral vectors and methods for their preparation and use
#2338Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
#2339Polypeptides that Bind IL-23R
#2340Combinatorial Libraries Based on C-type Lectin-like Domain
#2341Anti-viral fusion peptides
#2342VACCINES DIRECTED TO LANGERHANS CELLS
#2343Targeted Coagulation Factors and Method of Using the Same
#2344ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS
#2345Methods of reducing excitotoxicity-induced retinal ganglionic neuron degeneration by an orthodenticle HOMOLOG2 (OTX2) homeoprotein
#2346Compound
#2347Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof
#2348Compositions and Methods for Treatment of Neoplastic Disease
#2349Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
#2350FUSION OR LINKED PROTEINS WITH EXTENDED HALF LIFE
#2351COMPLEXING SYSTEM
#2352High affinity NY-ESO T cell receptor
#2353CHIMERIC POLYPEPTIDES AND THEIR USE
#2354Fusion proteins
#2355IGE DIRECTED DNA VACCINATION
#2356Antibody-light fusion products for cancer therapeutics
#2357RECOMBINANT NEWCASTLE DISEASE VIRUS
#2358High affinity NY-ESO T cell receptors
#2359ENZYME PRODRUG CANCER THERAPY SELECTIVELY TARGETED TO TUMOR CELLS OR TUMOR VASCULATURE AND METHODS OF PRODUCTION AND USE THEREOF
#2360Immunogenic control of tumours and tumour cells
#2361Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
#2362Fusion proteins comprising antibody and HPV E6 and E7 antigens
#2363Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#2364Nucleic acid molecules encoding soluble frizzled (FZD) receptors
#2365COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
#2366POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION
#2367COMPOSITIONS OF TOLL-LIKE RECEPTOR AGONISTS AND PAPILLOMAVIRUS ANTIGENS AND METHODS OF USE THEREOF
#2368Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
#2369DRUG DELIVERY SYSTEMS USING FC FRAGMENTS
#2370BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF
#2371Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
#2372Lectin compositions and methods for modulating an immune response to an antigen
#2373PSEUDOMONAS EXOTOXIN A CD4+ T-CELL EPITOPES
#2374DNA immunization protocols
#2375Fusion molecules and IL-15 variants
#2376COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
#2377Cytotoxins comprising modified bouganin toxin for the treatment of cancer
#2378Fusion proteins
#2379HIGH AFFINITY FLUOROCHROME BINDING PEPTIDES
#2380Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
#2381Immune modulation via C-type lectin
#2382Protease activatable interferon alpha proprotein
#2383Targeting pseudotyped retroviral vectors
#2384Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
#2385Humanized GM-CSF antibodies
#2386THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE
#2387Phage displayed cell binding peptides
#2388Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
#2389TARGETED BIOCIDES
#2390Polypeptides that bind Trail-R1 and Trail-R2
#2391Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
#2392Bispecific fusion protein having therapeutic and diagnostic potential
#2393Compositions of PD-1 antagonists and methods of use
#2394Cytokine-based fusion proteins for treatment of multiple sclerosis
#2395Reducing the immunogenicity of fusion proteins
#2396COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY
#2397ANTIBODY VACCINE CONJUGATES AND USES THEREFOR
#2398Phage derived antimicrobial activities
#2399Chimeric viral envelopes
#2400Fusion molecules and IL-15 variants